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We welcome the remarks of Mahlknecht and colleagues regarding the practical application 
of the MDS research criteria for prodromal Parkinson’s Disease. Before commenting further 
on our own use of these, it is worth revisiting how and why these criteria were established.  
The MDS criteria were devised as a data-driven, objective method of estimating an 
individual’s absolute probability of being in the prodromal phase of Parksinson’s Disease (PD)1 
by incorporating a range of risk factors and prodromal markers. The weighting assigned to 
each variable is determined solely from the evidence of its predictive value. The criteria can 
be used with as much or as little data as one has available; the accuracy will improve the more 
variables are included. Importantly, the purpose is to estimate whether prodromal 
neurodegeneration is present, not when an individual will convert to PD.  
 
In light of this, it is clear that in a cohort with polysomnographically proven RBD we would 
expect ≥75% of patients to fulfil these criteria, given the known long term risk in this 
population2-4. The high likelihood ratio (LR) attributed to RBD reflects this and, as 
acknowledged in our original discussion5, the high probabilities seen in RBD cohorts are 
largely accounted for by the presence of RBD itself. We agree that many of the other risk 
factors have a negligible effect in comparison, but we do not consider this a weakness of the 
criteria per se, as it simply reflects the clinical reality.  
 
It is clear that excluding the most important marker of prodromal PD will dramatically reduce 
the accuracy of an individual’s probability estimate. Mahlknecht and colleagues nicely 
illustrate this in their letter as excluding RBD in their case series (20 patients) results in just 
10% of individuals meeting criteria for probable prodromal PD. This is very similar to what we 
reported in our original paper, where amongst our cohort of 171 RBD patients only 12% (95% 
confidence interval 7.8-18.2%) met criteria for probable prodromal PD without the PSG-
confirmed-RBD LR5. The mean probability in this case is 30.6% (standard deviation 30.6, 
median 17.0%). These are likely to be substantial underestimates of the long term risk, as 
attested by the study of Fereshtehnejad and colleagues, where the sensitivity of the MDS 
criteria fell to 14.6% when excluding RBD status6. 
 
We do not agree that this renders the inclusion of PSG futile, but it does highlight the 
importance of using models in their appropriate context. Within a cohort of patients with 
  
PSG-proven RBD it makes no difference to between-patient stratification whether the LR for 
PSG is included or not, since all subjects test positive for this (one would simply need to adjust 
the probability threshold used). However, it is important to note that we do not know the 
extent to which RBD interacts with other risk factors or neurodegenerative markers. We 
therefore are more cautious in making any assumptions as to the effects of removing RBD 
from the equation when applying MDS criteria to RBD patients. This caveat applies to control-
RBD comparisons as much as to RBD patient stratification. For example, we have shown that 
RBD is strongly associated with many non-motor features that are included in the MDS 
criteria, perhaps to an even greater extent than early PD overall5. This suggests that RBD 
patients may represent the prodromal phase of a subtype of Parkinsonism with higher MDS 
probability scores than prodromal patients in general, even without the PSG LR. It would 
therefore be wrong to assume that one could directly compare RBD patients with population 
cohorts using MDS criteria simply by removing the RBD weighting. It may be that the LRs taken 
from population-based studies are not generalizable for RBD cohorts and hence the derived 
probabilities may be misleading. 
 
One must be equally cautious when attempting to estimate sensitivity and specificity for 
conversion within an RBD cohort, as Mahlknecht et al have done with our data. The gold 
standard outcome to be used in such calculations against the MDS criteria estimates is life 
time development of PD/DLB, and not merely early conversion. As acknowledged in the 
original paper by Berg and colleagues, short duration studies like ours will substantially 
underestimate the specificity in particular1.  
 
We do not view the comparison between RBD patients and controls as the primary measure 
of interest with regards to the application of the MDS criteria in our own analyses. 
Nevertheless, the lack of PSG in controls is unlikely to have made a significant difference to 
this since RBD is rare in the general population and even if a few cases of true RBD were 
inadvertently included in the control group, there would be little effect on the median 
probability reported. We presume that similar reasoning was used by the Sleep Innsbruck 
Barcelona Group to justify the inclusion of dopamine transporter imaging in RBD patients but 
not controls in their recent dataset7.   
  
The comparison between RBD and PD is also not relevant here, since we already know that 
the true probability in PD patients is 100%. Rather than looking at between-group 
comparisons, the motivation for including the MDS criteria in our analysis was to illustrate 
the following three points: firstly, the estimated prevalence of probable prodromal PD in our 
RBD cohort (74% of patients meeting criteria) is in line with expected long term outcomes. 
Secondly, using simple clinical measures in control participants, the false positive rate is 
estimated to be low. This is important since large scale screening will only be possible with 
simple measures, and a low false positive rate will be desirable in the design of 
neuroprotective trials. Thirdly, without additional invasive (and costly) investigations, the 
sensitivity is estimated to be low, given the result in our early, untreated PD cohort. It is likely, 
therefore, that a two-step screening process would be required at the population level, 
starting with simple, accessible tests followed by more expensive and invasive investigations 
such as PSG and dopaminergic neuroimaging. 
 
In response to the other queries raised: a temporal association between RBD onset and 
initiation of antidepressants was an exclusion criterion for our study. The mean interval 
between RBD symptom onset and inclusion was 7.1 years (SD 6.3), and between RBD 
diagnosis and inclusion was 1.9 years (SD 2.1). Epworth Sleepiness Scale (ESS) scores for the 
three groups were as follows: control participants, mean 5.7 (SD 3.7); RBD patients, mean 7.2 
(SD 4.7); PD patients, mean 6.2 (SD 4.1). Adjusting for age and gender in a linear regression 
model, the difference in ESS scores between controls and RBD patients was significant (p = 
0.002) whilst other pairwise comparisons were not.  
 
To conclude, the caveats raised by Mahlknecht and colleagues, along with many others 
acknowledged in the original MDS criteria paper, are important to consider when assessing 
for the presence of prodromal PD. We must also, however, be wary of modifying the MDS 
criteria without a sound evidence base. Further risk stratification models are likely to be 
needed in RBD cohorts, particularly given the wide variation in lead times to conversion. 
These may include the rates at which markers change over time in addition to absolute 
values8. DAT SPECT imaging might indeed be an important contributor to such models, and 
collection of this alongside other imaging data is underway in our cohort. Ultimately, 
  
accumulation of longitudinal data will be the crucial factor in accurately evaluating and 
refining any risk stratification tool.  
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